Table 1.
Serum sex steroid levels
| Castrate (n = 10) |
Low T/E (n = 10) |
Normal T/E (n = 11) |
Normal T/Low E (n = 13) |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Week 2 | Week 4 | Baseline | Week 2 | Week 4 | Baseline | Week 2 | Week 4 | Baseline | Week 2 | Week 4 | P Value | |
| Serum total testosterone, ng/ml | 4.9 (1.5) | 1.0 (1.5) | 0.2 (0.2) | 5.3 (1.6) | 3.0 (1.2) | 4.1 (2.1) | 4.9 (1.4) | 5.6 (3.9) | 7.2 (4.6) | 6.1 (1.8) | 5.2 (2.7) | 7.4 (3.3) | <0.0001 |
| Serum 17β-estradiol, pg/ml | 24.4 (6.8) | 6.7 (4.7) | 5.1 (2.2) | 29.7 (12.5) | 13.8 (5.7) | 14.6 (10.0) | 25.4 (7.4) | 23.0 (17.2) | 29.8 (18.5) | 26.4 (6.4) | 1.6 (1.5) | 3.7 (1.8) | <0.0001 |
Data are shown as means (SD). Baseline and on-treatment serum sex steroid levels for the 44 subjects included in the analyses. Castrate: placebo transdermal gel and placebo tablets (Castrate group); Low T/E: low-dose testosterone gel (1.25 g of 1.62% gel; AndroGel) and placebo tablets; Normal T/E: full replacement dose testosterone gel (5 g of 1.62% gel) and placebo tablets; Normal T/Low E: full replacement dose testosterone gel and the aromatase inhibitor letrozole (Apotex). P values represent time-by-group interactions from repeated-measures (RM)-ANOVA comparing all treatment arms at baseline and week 4.